Fentanyl Transdermal Articles
European Commission enforcement action in pharmaceutical sector following sector inquiry
31 January 2013
Teva's 1st-qtr profit more than triples
6 May 2009
J&J 1st qtr hit by market drop; keeps guidance
15 April 2009
MRI danger for Teva patch and others
16 March 2009
J&J to pay $4.5M for "misleading physicians"
9 March 2009
J&J subsidiaries ordered to pay $16.6M over Duragesic death
24 November 2008
US FDA approves Teva's fentanyl patch
27 October 2008
J&J/Actavis recall US lots of fentanyl patches
25 February 2008
Mylan's earnings soar 94% in fiscal 2nd-qtr
12 November 2007
Mylan updates on fentanyl expectations
14 August 2006
Mylan sees record 1st-qtr 2007 revenues
7 August 2006
J&J's 1st-qtr 2006 earnings up 16.4%, but sales weak
24 April 2006
Mylan sees solid third-quarter results
13 February 2006
J&J's 4th-qtr 2005 sales drop 1.1% on low Rx
30 January 2006
US FDA posts DSOB meeting summary
15 August 2005
NZ Pharmac gets budget boost, OKs new Rx uses
8 August 2005
Mylan sees 12% drop in fourth-qtr profit
23 May 2005
Janssen launches Durogesic
7 March 2005
Mylan's 3rd-qtr revenues slump 17%
14 February 2005
Mylan's pain patch gets FDA clearance
7 February 2005
J&J's 4th-qtr net earnings plunge 34%
31 January 2005
Par buys 5% of Abrika and signs generics deal
13 December 2004
Mylan lowers 2nd-qtr earnings forecast
25 October 2004
Stock Commentary - New York
6 September 2004
Mylan to appeal fentanyl ruling
23 August 2004
J&J 4th-qtr EPS up 35%, sales rise 20%
26 January 2004
Stock Commentary - New York
8 December 2003
Stock Commentary - New York
17 November 2003
J&J raises forecast on strong 3rd quarter
20 October 2003
Acquisition charges hit J&J 2nd-qtr results
21 July 2003
J&J
22 July 2002
J&J earnings climb 18.2% in 1st qtr
22 April 2002
J&J posts healthy increase in sales and earnings for 2001
28 January 2002
Japanese approvals for GSK and Janssen-Kyowa
9 October 2001
J&J beats forecasts with 14% EPS rise
18 April 2001
J&J sales up despite Propulsid problem
24 January 2001
Johnson & Johnson earnings climb 14%
18 October 2000
J&J beats forecasts with 2nd qtr earnings
20 July 2000
Johnson & Johnson net earnings rise 15.5%
19 April 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
US Majors Post Strong Earnings For 3rd Quarter
15 October 1998
Latest Wave Of US 1st Quarter Results
7 May 1998
J&J 1st Quarter Earnings Rise But Strong $ Hits Sales
15 April 1998
Trend For 1997 Strong Sales Continues In USA
5 February 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
J&J 3rd Qtr Earnings Rise But Sales Hit By Strong $
16 October 1997
Solid Growth For US Firms Despite Strong $
24 July 1997
Strong $ Impact On 1st Qtr At Johnson & Johnson
22 April 1997
Strong Earnings Continue At Major US Drug Firms
10 February 1997
Significant Increases For US Drug Firms In 1996
3 February 1997
Major US Drug Cos Post Strong Results In 3rd Qtr
28 October 1996
Transition For AHP in 1995; Year-End Results
5 February 1996
End Of Year Encouraging For US Companies
6 February 1995
Janssen-Cilag's Durogesic Patch Launched In UK
30 January 1995
Alza Receives Warning From FDA
22 August 1994
RESTRUCTURING CHARGES DEPRESS LILLY AND E KODAK
14 February 1994
ALZA IN LAWSUIT
31 January 1994
JANSSEN ISSUES PATCH SAFETY WARNING
24 January 1994
NICOTINE PATCH COs SUFFER DECLINE IN US SALES
2 August 1993
ALZA is STILL A STRONG BUY
14 December 1992
US RESULTS 3RD QTR
2 November 1992
ANALYST'S ESTIMATES OF US THIRD QTR EARNINGS
12 October 1992
ANESTHETIC PRODUCT PACT
20 January 1992
ALZA PRODUCT PROMOTIONS
20 January 1992
Showing 1-87 of 87 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
